Technical Analysis for INNT - Innovate Biopharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 1.37 -4.20% -0.06
INNT closed down 4.2 percent on Wednesday, May 22, 2019, on 37 percent of normal volume. The bears made the stock sink to a new 52-week low.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical INNT trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
New 52 Week Closing Low Bearish 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
New 52 Week Closing Low Bearish -4.20%
New Downtrend Bearish -4.20%
Doji - Bullish? Reversal -4.20%
New 52 Week Low Weakness -4.20%

Older signals for INNT ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Innovate Biopharmaceuticals, Inc., formerly Monster Digital, Inc., is a clinical stage biotechnology company. The Company is focused on developing novel autoimmune and inflammation therapeutic drugs. Its lead drug candidate, larazotide acetate (INN-202) is a tight junction regulator. Its other products include INN-108 and INN-329 (Secretin). The Company’s INN-108 is a novel small molecule comprised of two active parts with anti- inflammatory and immunodulatory properties coupled through an azo bond. The Company is developing INN-108 as a therapeutic for Ulcerative Colitis (UC). Its Secretin stimulated magnetic resonance cholangiopancreatography (MRCP) is a ionizing, radiation-free assessment of the pancreaticobiliary system. The Company has completed a phase II b clinical trial for celiac disease for INN-202. It is developing INN-108 in a phase II trial for inflammatory bowel disorders, mild to moderate UC and a Gastrointestinal (GI) orphan disease.
Medicine Biotechnology Biopharmaceutical Medical Specialties Autoimmune Diseases Radiation Inflammation Inflammatory Bowel Disease Ulcerative Colitis Abdominal Pain Diarrhea Colitis Digestive Diseases Celiac Disease Gastrointestinal Tract
Is INNT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 29.09
52 Week Low 1.35
Average Volume 1,154,489
200-Day Moving Average 3.3058
50-Day Moving Average 1.7834
20-Day Moving Average 1.593
10-Day Moving Average 1.546
Average True Range 0.1461
ADX 28.42
+DI 15.2088
-DI 16.3983
Chandelier Exit (Long, 3 ATRs ) 1.9617
Chandelier Exit (Short, 3 ATRs ) 1.7883
Upper Bollinger Band 1.8755
Lower Bollinger Band 1.3105
Percent B (%b) 0.11
BandWidth 35.467671
MACD Line -0.0854
MACD Signal Line -0.0792
MACD Histogram -0.0062
Fundamentals Value
Market Cap 12.81 Million
Num Shares 9.35 Million
EPS -0.89
Price-to-Earnings (P/E) Ratio -1.54
Price-to-Sales 1.94
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.52
Resistance 3 (R3) 1.53 1.49 1.50
Resistance 2 (R2) 1.49 1.45 1.49 1.49
Resistance 1 (R1) 1.43 1.43 1.41 1.42 1.48
Pivot Point 1.39 1.39 1.38 1.39 1.39
Support 1 (S1) 1.33 1.35 1.31 1.32 1.26
Support 2 (S2) 1.29 1.33 1.29 1.25
Support 3 (S3) 1.23 1.29 1.25
Support 4 (S4) 1.22